POSA28 Reductions in Migraine and Headache Days After Initiating Fremanezumab for Patients with Migraine and Prior Use of Another Monoclonal Antibody Targeting the CGRP Pathway in a US Real-World Setting.

MLA

Driessen, M., et al. “POSA28 Reductions in Migraine and Headache Days After Initiating Fremanezumab for Patients with Migraine and Prior Use of Another Monoclonal Antibody Targeting the CGRP Pathway in a US Real-World Setting.” Value in Health, vol. 25, no. 1, Jan. 2022, p. S23. EBSCOhost, https://doi.org/10.1016/j.jval.2021.11.101.

APA

Driessen, M., Patterson-Lomba, O., Mu, F., Thompson, S., Seminerio, M., Carr, K., Sun, R., Totev, T., Yim, E., Ayyagari, R., & Cohen, J. (2022). POSA28 Reductions in Migraine and Headache Days After Initiating Fremanezumab for Patients with Migraine and Prior Use of Another Monoclonal Antibody Targeting the CGRP Pathway in a US Real-World Setting. Value in Health, 25(1), S23. https://doi.org/10.1016/j.jval.2021.11.101

Chicago

Driessen, M, O Patterson-Lomba, F Mu, S Thompson, M Seminerio, K Carr, R Sun, et al. 2022. “POSA28 Reductions in Migraine and Headache Days After Initiating Fremanezumab for Patients with Migraine and Prior Use of Another Monoclonal Antibody Targeting the CGRP Pathway in a US Real-World Setting.” Value in Health 25 (1): S23. doi:10.1016/j.jval.2021.11.101.